Across TCGA pan-cancer cohorts, ANKRD20A8P Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKRD20A8P data layer compared with 22 for mass-spec protein.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ANKRD20A8P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD20A8P expression acts as an unfavorable survival marker.
OV, LUAD, and COAD are the cancer types where ANKRD20A8P Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.